Uncontrolled Hypertension in Cardio-Renal-Metabolic Diseases: Real-World Insights on Patient Profiles and Management Patterns From iCaReMe Global Registry.
Kamlesh Khunti, Mustafa Arici, Carol Pollock...
https://pubmed.ncbi.nlm.nih.gov/42694927/Actively Recruiting
Led by AstraZeneca · Updated on 2026-09-09
35000
Participants Needed
76
Research Sites
N/A
Total Duration
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.
CONDITIONS
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 years
Participants provide health information and clinical data through their healthcare providers. Data is collected both retrospectively and prospectively using a secure electronic system to capture patient characteristics, treatments, and outcomes.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Kamlesh Khunti, Mustafa Arici, Carol Pollock...
https://pubmed.ncbi.nlm.nih.gov/42694927/AstraZeneca
Lead Sponsor